Literature DB >> 10782624

Cost analysis of glaucoma medications.

S D Vold1, D A Wiggins, J Jackimiec.   

Abstract

PURPOSE: To evaluate the yearly cost in 1998 of glaucoma medications to patients and to the Health Plan at a university-affiliated teaching hospital with its own health maintenance organization.
MATERIALS AND METHODS: Data concerning Health Plan glaucoma-medication prescriptions for 1998 were retrieved from the hospital pharmacy database.
RESULTS: The most costly medication per patient per year was latanoprost (Xalatan; Pharmacia & Upjohn, Kalamazoo, MI [$337]), followed by betaxolol hydrochloride (Betoptic-S; Alcon, Fort Worth, TX [$336]), dorzolamide (Trusopt; Merck & Co., West Point, PA [$288]), brimonidine tartrate (Alphagan; Allergan Pharmaceuticals, Irvine, CA [$260]), timolol maleate 0.5% in a gel-forming solution (Timoptic-XE 0.5%; Merck & Co., West Point, PA [$199]), levobunolol hydrochloride (Betagan; Allergan Pharmaceuticals, Irvine, CA [$195]), and generic timolol maleate 0.5% ($132). Cost per unit was greatest for Betoptic-S ($51), exceeding that of Trusopt ($43) and Xalatan ($43), Alphagan ($42), Betagan ($38), Timoptic-XE 0.5% ($32), and timolol maleate 0.5% ($27).
CONCLUSION: Variability in the cost of medications may influence the long-term medical management of glaucoma patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782624     DOI: 10.1097/00061198-200004000-00004

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  4 in total

Review 1.  Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? The controversy.

Authors:  I Goldberg
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

Review 2.  The economic implications of glaucoma: a literature review.

Authors:  Jordana K Schmier; Michael T Halpern; Mechelle L Jones
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma.

Authors:  Joanna H Queen; Robert M Feldman; David A Lee
Journal:  Am J Ophthalmol       Date:  2015-11-18       Impact factor: 5.258

4.  Cost of glaucoma treatment in a developing country over a 5-year period.

Authors:  Gabriel Lazcano-Gomez; María de Los Angeles Ramos-Cadena; Margarita Torres-Tamayo; Alejandra Hernandez de Oteyza; Mauricio Turati-Acosta; Jesús Jimenez-Román
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.